RSS   Newsletter   Contact   Advertise with us
Post Online Media

Sorrento names Miranda Toledano as EVP, corporate development

SorrentoSorrento Therapeutics, Inc., a biopharmaceutical company, appointed Miranda Toledano as EVP of corporate development of Sorrento and president of LA Cell, Sorrento's joint venture with City of Hope.
Article continues below

READ MORE Sorrento names Douglas Ebersole to board

Ms. Toledano joins Sorrento with 18 years of principal investment, financing and strategic advisory experience in the biopharmaceutical sector.

Since 2012, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co., now an FBR company, where she completed over 110 IPO and follow on equity offerings totaling over $4 billion in aggregate value.

Prior to joining MLV, she served in the investment group of Royalty Pharma where she focused on acquiring best in class biologic therapeutics targeting oncology, auto-immune and neurodegenerative indications.

From 1998 to 2003, she served as a Senior Manager at Ernst & Young (Israel) where she established the Life Sciences Corporate Finance group.

Ms. Toledano received a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy